Wedbush analyst David Nierengarten upgraded AnaptysBio to Outperform from Neutral with a price target of $34, up from $20.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ANAB:
- Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- ANAB Earnings this Week: How Will it Perform?
- Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
- AnaptysBio initiated with a Buy at BTIG
- Palo Alto Networks, Home Depot downgraded: Wall Street’s top analyst calls